Optimization of Treatment of Patients with Ischemic Heart Disease Combined with Nonalcoholic Fatty Liver Disease
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
The objective: of this work is to determine the effectiveness of hepatoprotection of heparisin in patients with unstable angina in combination with non-alcoholic fatty liver disease.
Material and methods. 42 patients with unstable angina were examined, including 24 patients with unstable angina in combination with non-alcoholic fatty liver disease, 18 patients with unstable angina, and 20 control subjects. Patients with combined pathology received a hepatoprotection. Patients were evaluated for lipid spectrum and functional status of the liver.
Results. When evaluating the blood lipid spectrum in patients with unstable angina revealed dyslipidemia. After treatment in both groups, there was an improvement in lipogram. In patients with unstable angina with concomitant NAFLD, some increase in the level of transaminases and a decrease in their level after treatment was noted.
Conclusion. The use of heparisin in patients with unstable angina in combination with NAFLD had a positive effect on the functional state of the liver and contributed to the reduction of transaminases after treatment. There was no significant effect of heparisin on blood lipid spectrum enhancement.##plugins.themes.bootstrap3.article.details##
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
References
Гандзюк В.А., 2014. Аналіз захворюваності на ішемічну хворобу серця // Український кадіологічний журнал. 3:45-52.
Корнійчук І.Ю., 2010. Епідеміологія, методи діагностики та лікування неалкогольної хвороби печінки на сучасному етапі // Буковинський медичний вісник. 4 (56):159-162.
Степанов Ю.М., Ягмур В.Б., Саленко А.В., 2018. Гліциризинова кислота: патофізіологічні аспекти формування фіброзу та ефективність у лікуванні захворювань печінки // Gastroenterologia. 52(3):150-156. doi: 10.22141/2308-2097.52.3.2018.141846.
Харченко Н.В., 2017. В поиске идеального антифибротического препарата: как сказать «нет» фіброзу печени? // Здоров’я України. 24:1-7.
Byrne C.D., Olufadi R., Bruce K.D. et al., 2009. Metabolic disturbances in non-alcoholic fatty liver disease // Clin Sci (Lond). 116(7):539-64. doi: 10.1042/CS20080253.
Karr S., 2017. Epidemiology and management of hyperlipidemia // Am. J. Manag. Care. 23,9:139-148.
Lee K.W., Hill J.S. et al., 2006. Relative value of multiple plasma biomarkers as risk factors for coronary artery disease and death in an angiography cohort // CMAJ. 174 (4):461-466.
Levene A.P., Goldin R.D., 2012. The epidemiology, pathogenesis and histopathology of fatty liver disease // Histopathology. 61 (2):141–152 doi: 10.1111/j.1365-2559.2011.04145.x
Matsuzawa Y., 2015. Treating coronary disease and the impact of endothelial dysfunction // Prog Cardiovasc Dis. 57(5):431-442.
Nichols M., Townsend N., Scarborough P. et al., 2014. Cardiovascular disease in Europe 2014: epidemiological update // Eur Heart J. 35:2950-2959.
Pantsulaia I., Iobadze M. et al., 2015. Lipid profile and cytokines interactions during successful aging // Georgian Med News. 243:46-51.
Patil R., Sood G.K., 2017. Non-alcoholic fatty liver disease and cardiovascular risk // World J Gastrointest Pathophysiol. 15;8(2):51–58. doi: 10.4291/wjgp.v8.i2.51.
Townsend N., Nichols M., Scarborough P. et al., 2015. Cardiovascular disease in Europe: epidemiological update 2015 // Eur Heart J. 36:2696-2705.
Vilar C.P., Cotrim H.P., Florentino G.S. et al., 2013. Association between nonalcoholic fatty liver disease and coronary artery disease // Rev Assoc Med Bras (1992). 59(3):290-7. doi: 10.1016/j.ramb.2012.11.006.
Vilar C.P., Cotrim H.P., Florentino G.S. et al., 2015. Nonalcoholic fatty liver disease in patients with coronary disease from a Brazil northeast area // Arq. Gastroenterol. 52 (2):110-16 http://dx.doi.org/10.1590/S0004-28032015000200007.
